Tempus AI, Inc.: Beat — EPS $0.07, Revenue $411.54M
Earnings BeatQ3 2026 · Pre-market
Did Tempus AI, Inc. (TEM) beat earnings today?
Yes, Tempus AI, Inc. (TEM) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+187.50% surprise
$0.07Actual
Expected: -$0.08
vs. year ago +164.0%
Total Revenue+0.55% surprise
$411.54MActual
Expected: $409.3M
vs. year ago +23.0%
Released Nov 02 · 7:00 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $411.54M | $334.21M | +23.0% |
| Revenue detail — reported lines | |||
| └─Diagnostics | $303.47M | $252.88M | +20.0% |
| └─Data and applications | $108.07M | $81.33M | +33.0% |
| Net Loss | ($14.85M) | ($79.98M) | - |
| GAAP Basic EPS | -$0.08 | -$0.46 | - |
| GAAP Diluted EPS | -$0.08 | -$0.46 | - |
| Non-GAAP Basic EPS | $0.07 | -$0.11 | - |
| Non-GAAP Diluted EPS | $0.07 | -$0.11 | - |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY26 Outlook | Expected |
|---|---|---|---|
| Revenue | — | $1.60B-$1.605B (~25% YoY) | $1.6BBeat +0.16% |
| Adjusted EBITDA | — | ~$65M | — |
Business Highlights
- ➤Announced a five-year BMS collaboration licensing oncology data and models.
- ➤BMS and Pathos licensed Alzheimer’s and dementia data for five years.
- ➤Collaborated with Merck and Moderna on potential INT commercialization.
- ➤Cleared regulatory review for the pending Personalis acquisition.
- ➤Received FDA 510(k) clearances for Tempus ECG-PH and ECG-MR.
- ➤Launched an initiative for 100,000 whole genomes linked to longitudinal clinical data.
- ➤Expanded its non-invasive AI cardiology footprint with ECG-PH and ECG-MR.
Management Commentary
Eric Lefkofsky, founder and CEO of Tempus
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications.”
Eric Lefkofsky, founder and CEO of Tempus
“These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”